via Wistar Institute
Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR).
These finding were published today in Nature.
The World Health Organization (WHO) has declared AMR as one of the top 10 global public health threats against humanity. It is estimated that by 2050, antibiotic-resistant infections could claim 10 million lives each year and impose a cumulative $100 trillion burden on the global economy. The list of bacteria that are becoming resistant to treatment with all available antibiotic options is growing and few new drugs are in the pipeline, creating a pressing need for new classes of antibiotics to prevent public health crises.
“We took a creative, double-pronged strategy to develop new molecules that can kill difficult-to-treat infections while enhancing the natural host immune response,” said Farokh Dotiwala, M.B.B.S., Ph.D., assistant professor in the Vaccine & Immunotherapy Center and lead author of the effort to identify a new generation of antimicrobials named dual-acting immuno-antibiotics (DAIAs).
Existing antibiotics target essential bacterial functions, including nucleic acid and protein synthesis, building of the cell membrane, and metabolic pathways. However, bacteria can acquire drug resistance by mutating the bacterial target the antibiotic is directed against, inactivating the drugs or pumping them out.
“We reasoned that harnessing the immune system to simultaneously attack bacteria on two different fronts makes it hard for them to develop resistance,” said Dotiwala.
He and colleagues focused on a metabolic pathway that is essential for most bacteria but absent in humans, making it an ideal target for antibiotic development. This pathway, called methyl-D-erythritol phosphate (MEP) or non-mevalonate pathway, is responsible for biosynthesis of isoprenoids — molecules required for cell survival in most pathogenic bacteria. The lab targeted the IspH enzyme, an essential enzyme in isoprenoid biosynthesis, as a way to block this pathway and kill the microbes. Given the broad presence of IspH in the bacterial world, this approach may target a wide range of bacteria.
Researchers used computer modeling to screen several million commercially available compounds for their ability to bind with the enzyme, and selected the most potent ones that inhibited IspH function as starting points for drug discovery.
Since previously available IspH inhibitors could not penetrate the bacterial cell wall, Dotiwala collaborated with Wistar’s medicinal chemist Joseph Salvino, Ph.D., professor in The Wistar Institute Cancer Center and a co-senior author on the study, to identify and synthesize novel IspH inhibitor molecules that were able to get inside the bacteria.
The team demonstrated that the IspH inhibitors stimulated the immune system with more potent bacterial killing activity and specificity than current best-in-class antibiotics when tested in vitro on clinical isolates of antibiotic-resistant bacteria, including a wide range of pathogenic gram negative and gram positive bacteria. In preclinical models of gram negative bacterial infection, the bactericidal effects of the IspH inhibitors outperformed traditional pan antibiotics. All compounds tested were shown to be nontoxic to human cells.
“Immune activation represents the second line of attack of the DAIA strategy,” said Kumar Singh, Ph.D., Dotiwala lab postdoctoral fellow and first author of the study.
“We believe this innovative DAIA strategy may represent a potential landmark in the world’s fight against AMR, creating a synergy between the direct killing ability of antibiotics and the natural power of the immune system,” echoed Dotiwala.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
New class of antibiotics
- Matching Right Patients to Right Drugs Is Key With New Entrants to Heart Failure Marketon May 18, 2021 at 6:28 am
An introduction to new therapies and Monday's late-breaking session highlight the new options in heart failure treatment during the 70th Scientific Session of the American College of Cardiology.
- 360 new cases of Covid-19 reported last eveningon May 17, 2021 at 11:43 pm
New cases of Covid-19 have decreased by 2 per cent over the past week. 2,870 new cases have been reported in the past seven days - 61 fewer than the previous week. That's despite ...
- A T-cell player with backing from Roche takes next big step for BiTE drugs with 'on-off' switch to avoid toxicityon May 17, 2021 at 2:38 pm
The bispecific T cell engager field is absolutely packed with big-name players who have crowded in despite some high-profile failures in the class. Now, a Bay Area biotech thinks it may have the key ...
- New study may help develop senolytic drugs that target senescent immune cellson May 12, 2021 at 9:52 pm
In a study recently published in Nature University of Minnesota Medical School researchers found that senescent immune cells are the most dangerous type of senescent cell.
- Novel structure found in tumor cells may open door to new kinds of cancer therapieson May 12, 2021 at 5:24 am
In 2015, researchers at UC San Francisco found a structure inside of tumor cells that biologists had never seen before. Even more surprising, a closer examination of the structure revealed that it ...
Go deeper with Google Headlines on:
New class of antibiotics
Go deeper with Bing News on:
Drug-resistant bacterial pathogens
- Baz Brandings, Trades LLP partner with Polyamyna Nanotech Inc for antimicrobial products in Indiaon May 18, 2021 at 3:25 am
Intending to increase the level of hygiene and cleanliness, Baz Brandings and Trades LLP has partnered with Polyamyna Nanotech Incorporation (PNI), a Canadian-based Scientific Biotech company that ...
- Baz Brandings and Trades LLP confederates withon May 18, 2021 at 2:34 am
Intending to increase the level of hygiene and cleanliness Baz Brandings and Trades LLP has partnered with Polyamyna Nanotech Incorporation PNI a Canadian-b ...
- Conventional Meats Contaminated with Multi-Drug Resistant Bacteria, at Significantly Higher Rates than Organic Meatson May 17, 2021 at 9:13 pm
Organic meat is far less likely to be adulterated with multi-drug resistant bacteria (MDRB) than conventional meat, according a study published earlier this month in Environmental Health Perspectives.
- Research: ‘Last resort’ antibiotic bursts bacteria like a balloonon May 14, 2021 at 3:31 am
The findings could lead to the development of new treatments to defeat bacteria that have become resistant to other antibiotics.
- Organic meat less likely to be contaminated with multidrug-resistant bacteria, study suggestson May 13, 2021 at 5:00 am
Analysis also uncovers meats from processors that handle both organic and conventional retail meat may be less likely to be contaminated with pathogenic bacteria ...